Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier

AAPS Journal

Volumn 15, Issue 2, 2013, Pages 299-307

  Cisternino, Salvatore ^a,b   Chapy, Hélène ^a   André, Pascal ^a,b   Smirnova, Maria ^a   Debray, Marcel ^a   Scherrmann, Jean Michel ^a,b  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

blood brain barrier; nicotine; organic cation; proton antiporter; transporter

Indexed keywords

17 METHYLNALOXONE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AGMATINE; ANTIPORTER; BREAST CANCER RESISTANCE PROTEIN; CARNITINE; CHOLINE; CLONIDINE; CODEINE; DIPHENHYDRAMINE; DOPAMINE; HISTAMINE; MULTIDRUG RESISTANCE PROTEIN; NALOXONE; NICOTINE; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 3; ORGANIC CATION TRANSPORTER MATE1; ORGANIC CATION TRANSPORTER OCTN; ORGANIC CATION TRANSPORTER PMAT; OXYCODONE; PROTON ANTIPORTER; SEROTONIN; TETRYLAMMONIUM; TRAMADOL; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CELL PH; CONTROLLED STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MEMBRANE TRANSPORT; MICHAELIS MENTEN KINETICS; MOUSE; NICOTINE TRANSPORT; NONHUMAN; PASSIVE TRANSPORT; TISSUE DISTRIBUTION; TOBACCO DEPENDENCE;

ANIMALS; ANTIPORTERS; ATP-BINDING CASSETTE TRANSPORTERS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DIFFUSION; DIPHENHYDRAMINE; HYDROGEN-ION CONCENTRATION; KINETICS; MALE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NICOTINE; NONLINEAR DYNAMICS; ORGANIC CATION TRANSPORT PROTEINS; PERFUSION; TRAMADOL;

EID: 84877032878     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9434-6     Document Type: Article

References (42)

1. Samaha AN, Yau WY, Yang P, Robinson TE. Rapid delivery of nicotine promotes behavioral sensitization and alters its neurobiological impact. Biol Psychiatry. 2005;57(4):351-60.
2. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl). 2000;149(3):198-202.
3. Samaha AN, Robinson TE. Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci. 2005;26(2):82-7.
4. Berridge MS, Apana SM, Nagano KK, Berridge CE, Leisure GP, Boswell MV. Smoking produces rapid rise of [11C]nicotine in human brain. Psychopharmacology (Berl). 2010;209(4):383-94.
5. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.
6. Tournier N, Decleves X, Saubamea B, Scherrmann JM, Cisternino S. Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: Implications for neuropsychopharmacology. Curr Pharm Des. 2011;17(26):2829-42.
7. + antiporter that interacts with addictive drugs. J Cereb Blood Flow Metab. 2009;29(7):1293-304.
8. Fukada A, Saito H, Inui K. Transport mechanisms of nicotine across the human intestinal epithelial cell line Caco-2. J Pharmacol Exp Ther. 2002;302(2):532-8.
9. Fukada A, Saito H, Urakami Y, Okuda M, Inui K. Involvement of specific transport system of renal basolateral membranes in distribution of nicotine in rats. Drug Metab Pharmacokinet. 2002;17(6):554-60.
10. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol. 1984;247(3 Pt 2):H484-93.
11. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab. 2000;20(2):381-6.
12. Smith QR. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm Biotechnol. 1996;8:285-307.
13. Cattelotte J, Andre P, Ouellet M, Bourasset F, Scherrmann JM, Cisternino S. In situ mouse carotid perfusion model: glucose and cholesterol transport in the eye and brain. J Cereb Blood Flow Metab. 2008;28(8):1449-59.
14. Taylor CJ, Nicola PA, Wang S, Barrand MA, Hladky SB. Transporters involved in regulation of intracellular pH in primary cultured rat brain endothelial cells. J Physiol. 2006;576(Pt 3):769-85.
15. ChemSpider. The free chemical database. http://www.chemspider.com/ Chemical-Structure.917.html. Accessed 16 June 2012.
16. Oldendorf W, Braun L, Cornford E. pH dependence of blood-brain barrier permeability to lactate and nicotine. Stroke. 1979;10(5):577-81.
17. Putney Jr JW, Borzelleca JF. On the mechanisms of 14C-nicotine distribution in rat submaxillary gland in vitro. J Pharmacol Exp Ther. 1971;178(1):180-91.
18. Seelig A, Gottschlich R, Devant RM. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci USA. 1994;91(1):68-72.
19. Beschiaschvili G, Seelig J. Peptide binding to lipid bilayers. Nonclassical hydrophobic effect and membrane-induced pK shifts. Biochemistry (Mosc). 1992;31(41):10044-53.
20. Busto U, Bendayan R, Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet. 1989;16(1):1-26.
21. Aceto MD, Awaya H, Martin BR, May EL. Antinociceptive action of nicotine and its methiodide derivatives in mice and rats. Br J Pharmacol. 1983;79(4):869-76.
22. Ghosheh OA, Dwoskin LP, Miller DK, Crooks PA. Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2′-(14)C]nicotine. Drug Metab Dispos. 2001;29(5):645-51.
23. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33(1):165-74.
24. Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol. 2008;18(3):157-69.
25. Manda VK, Mittapalli RK, Bohn KA, Adkins CE, Lockman PR. Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010;115(6):1495-507.
26. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24(7):1227-51.
27. Itagaki S, Ganapathy V, Ho HT, Zhou M, Babu E, Wang J. Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter. Drug Metab Dispos. 2012;40(6):1138-43.
28. +/organic cation antiporter MATE1. Am J Physiol Renal Physiol. 2007;292(2):F593-8.
29. + in rat brain endothelial cells. Life Sci. 2007;81(8):664-72.
30. Dickens D, Owen A, Alfirevic A, Giannoudis A, Davies A, Weksler B, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012;83(6):805-14.
31. André P, Saubaméa B, Cochois-Guégan V, Marie-Claire C, Cattelotte J, Smirnova M, et al. Transport of biogenic amine neurotransmitters at the mouse blood-retina and blood-brain barriers by uptake1 and uptake2. J Cereb Blood Flow Metab. 2012;1989-2001.
32. Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr. 2000;130(4S Suppl):1016S-22S.
33. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos. 2008;36(10):2005-13.
34. Fischer W, Bernhagen J, Neubert RH, Brandsch M. Uptake of codeine into intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells. Eur J Pharm Sci. 2010;41(1):31-42.
35. Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, et al. Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. J Pharm Sci. 2011;100(9):3912-23.
36. Takami K, Saito H, Okuda M, Takano M, Inui KI. Distinct characteristics of transcellular transport between nicotine and tetraethylammonium in LLC-PK1 cells. J Pharmacol Exp Ther. 1998;286(2):676-80.
37. Zevin S, Schaner ME, Giacomini KM. Nicotine transport in a human choriocarcinoma cell line (JAR). J Pharm Sci. 1998;87(6):702-6.
38. Fischer W, Metzner L, Hoffmann K, Neubert RH, Brandsch M. Substrate specificity and mechanism of the intestinal clonidine uptake by Caco-2 cells. Pharm Res. 2006;23(1):131-7.
39. Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, Miyaguchi H, Iwata Y, et al. Uptake of 3,4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells. Biochim Biophys Acta. 2008;1778(1):42-50.
40. Mizuuchi H, Katsura T, Ashida K, Hashimoto Y, Inui K. Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol. 2000;278(4):G563-9.
41. Kanaan M, Daali Y, Dayer P, Desmeules J. Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: Focus on P-glycoprotein. Basic Clin Pharmacol Toxicol. 2009;105(3):199-206.
42. Suzuki T, Ohmuro A, Miyata M, Furuishi T, Hidaka S, Kugawa F, et al. Involvement of an influx transporter in the blood-brain barrier transport of naloxone. Biopharm Drug Dispos. 2010;31(4):243-52.